KEY TAKEAWAYS
- The study aimed to investigate the expression levels of lncRNA GJA9-MYCBP and PVT1 in blood samples from patients with ALL.
- Researchers noticed that the upregulation of lncRNA GJA9-MYCBP and PVT1 may serve as a potential diagnostic biomarker for ALL.
Acute lymphoblastic leukemia (ALL) is the most prevalent childhood blood cancer, with long noncoding RNAs (lncRNAs) implicated in its pathogenesis. LncRNAs are increasingly recognized as vital for diagnosing and prognosticating ALL.
Kamal Shahamiri and the team aimed to evaluate GJA9-MYCBP and PVT1 expression in ALL and healthy blood samples.
They performed an inclusive analysis using 40 pairs of ALL and healthy individual samples. Patients’ clinicopathological characteristics were evaluated alongside the expression of MYC and each candidate lncRNA using quantitative real-time PCR.
The results showed that lncRNA GJA9-MYCBP and PVT1 were significantly upregulated in ALL samples compared with healthy ones. Similarly, mRNA levels of MYC were increased in ALL samples than in control ones.
Receiver operating characteristic curve analysis indicated a satisfactory diagnostic efficacy (P-value <.0001), suggesting that lncRNA GJA9-MYCBP and PVT1 may serve as a diagnostic biomarker for ALL. Linear regression analysis unveiled positive correlations between the expression level of MYC and lncRNA GJA9-MYCBP and PVT1 in patients with ALL (P-values <.01).
The study concluded that the upregulation of lncRNA GJA9-MYCBP and PVT1 may signify a diagnostic biomarker for ALL, affirming their clinical diagnostic significance.
This study was funded by the Research Fund of Shahrekord University of Medical Science (5677).
Source: https://pubmed.ncbi.nlm.nih.gov/38994720/
Shahamiri K, Alghasi A, Saki N, et al. (2024). “Upregulation of the long noncoding RNA GJA9-MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia.” Cancer Rep (Hoboken). 2024 Jul;7(7):e2115. doi: 10.1002/cnr2.2115. PMID: 38994720; PMCID: PMC11240143.
